FDA Talks about Supply Chain Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Talks about Supply Chain Challenges
Pharmaceutical Technology has summarized recent statements by FDA officials on supply chain issues to provde the agency's most up-to-date views and expectations.


Pharmaceutical Technology


Supplier audits and certification

-Joe Famulare, deputy director, Office of Compliance, CDER


Table I: Supply chain changes since 2001.
"There are many initiatives on the table regarding third-party certification of suppliers, including parts of the Import Safety Action Plan and proposals on Capitol Hill," said Famulare. [The action plan calls for FDA to have the authority to require that producers of certain high-risk products in a particular country, under an agreement with that country, certify that their products meet FDA standards in order to export to the US.] "Other types of possible legislation changes may mandate that companies audit their suppliers," he added. "The main effort in this area is within ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (APIs), and the voluntary standards of the International Pharmaceutical Excipients Council and International Pharmaceutical Excipients Auditing," he said.

In another conference session, Famulare discussed supply chain qualification. "We have a task force within CDER compliance and there could be a guidance in that area forthcoming. We also enhanced ICH Q10: Pharmaceutical Quality System Section 2.7 regarding outsourcing to lay out a basic form of supply chain control by industry," said Famulare. "We're still studying the lessons learned from heparin and how to prevent it from happening again, but really, industry has to have the intelligence on their own supply chains."

External quality systems

-Joe Famulare

"For external supplier quality systems, whether you contract out or are getting supply, the regulations are specific regarding the testing to do to receive those materials and validate them," explained Famulare. "Now, with ICH Q10, having a program to audit that system and facility supplying you is very important—it goes beyond testing.... Having the intelligence to understand what may adversely impact that supply is also important. We don't expect the external supplier to have a mirror image of your quality system but we do expect it to mesh...and work with your quality system."

Future goals

-Deborah Autor, director, Office of Compliance, CDER

"We all share these new challenges and we all need to give serious thought to what we do.... It's not as simple as more inspections. We need to change the system," said Autor. "The old system was directed toward a domestic industry; that's not what we have anymore. Regulators and industry need to do more....

"We need more corporate responsibility. We're not in the shoe business. People are relying on these products to protect their health. We need to know where a product has been, where it was made, its integrity..." and so forth, she explained. "Management needs to be able to vouch for its products.... We can no longer say, 'FDA has to prove a drug product is bad.... We have to know a drug is 'good.'"

Autor also talked about how industy needs to shift to international cooperation in the longterm. "The job is simply too big for one regulator to do," she said. The European Medicines Agency/FDA joint inspection pilot is ongoing for information-sharing on European Union and US sites, and on API sites in third countries.

Author closed with the following: "In a global economy, manufacturers must bear clear responsibility for the integrity and quality of all ingredients. If you disagree with that, please let me know. Regulators must work together to adopt a worldwide approach. Together, we have to ensure that drugs are what we want ourselves and our families to take and to feel good about."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here